- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01695694
Violence and HIV Risk Among Women (VHRW)
HIV Risk Reduction for Women Reporting Intimate Partner Violence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The two foremost health problems impacting young adult women are STDs/HIV infection and intimate partner violence (IPV). STDs pose a significant public health issue in the US, particularly among women. The consequences of some STDs are more severe for women, and include infertility, pelvic inflammatory disease, and brain, cardiovascular, and organ damage. Women with STDs are at increased risk for HIV. The proportion of AIDS cases among US adult and adolescent women has more than tripled since 1985. Approximately 12,000 US women are infected with HIV annually, primarily through heterosexual contact. Also, in the US HIV is particularly affecting women of color and those in low-income urban areas.
IPV also affects many women. While the causal links between IPV and HIV risk or infection have not yet been established, emerging empirical evidence has drawn connections between IPV with HIV risk. Several researchers have highlighted the importance of developing sexual risk reduction interventions that address the growing concern of gender-based violence against women. Also, scholars are calling for HIV prevention programs aimed at women to be more comprehensive; for example, by combining them with STD screening or with programs designed to reduce violence against women. Despite this call, there are very few empirically tested interventions for prevention and treatment targeting women who are at risk for STDs/HIV and experience IPV in their intimate relationships. To address high risk sexual behaviors among women who experience gender-based violence in their intimate relationships, I have adapted an existing information-motivation-behavioral skills (IMB) STD/HIV prevention intervention for reducing high sexual risk-taking behaviors. The STD/HIV and IPV comprehensive intervention will address both sexual risk reduction and IPV risk; the intention is to help women to acquire knowledge, skills, and strategies that will reduce their risk for both STDs/HIV and IPV.
Aim 1: To assess the feasibility and acceptability of the adapted IMB STD/HIV prevention intervention by implementing the intervention with a sample of women who are at risk for HIV/STDs and experience IPV. To achieve this aim:
- 120 women who are at risk for HIV/STDs and have experienced IPV will be randomized either to receive the experimental prevention intervention or to attend a structurally similar drop-in enhanced support group at a domestic violence agency.
- Enrollment, attendance, and attrition data will be used to determine the feasibility of the intervention.
- The acceptability of the intervention will be appraised by analyzing pre- and post-intervention acceptability ratings completed by subjects and interventionists.
Aim 2: To gather preliminary evidence of the efficacy of the theoretically guided intervention using a controlled design. To achieve this aim:
- Women in the experimental and control groups will be assessed at baseline, post-intervention, and at a 3-month follow-up.
- Outcome analyses to calculate effect sizes for use in future power analyses for a larger RCT of the proposed intervention will include measures on primary variables of hypothesized risk antecedents, standard measures of protected and unprotected sex, and secondary variables such as mental health, self esteem, and IPV experiences.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Women will be eligible to participate in the research study if they meet the following criteria:
- between ages 18 and 49;
- heterosexually active;
- have experienced intimate partner violence in the last three months;
- have engaged in risky sexual behavior in the past three months;
- not currently pregnant or trying to become pregnant; and
- physically and psychologically capable of providing informed consent. All subjects will be required to provide written informed consent prior to enrolling in the study.
Exclusion Criteria:
Persons who meet one or more of the following criteria will be excluded from the study:
- men;
- women who have active psychosis or impaired mental status (confirmed with a Mini-Mental Status Exam);
- are unable to understand spoken English;
- are less than 18 years old or greater than 49 years old;
- are currently pregnant or trying to become pregnant
- women who are exclusively in same-sex relationships.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: community support group
|
|
|
Experimental: supporting positive and healthy relationships
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in sexual risk behavior at 3 months
Time Frame: at the completion of 3 months after the intervention
|
Sexual risk behavior is assessed by self-reported number sexual partners in the last three months and number of episodes of unprotected sex with each partner
|
at the completion of 3 months after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in experience of violence at 3 months
Time Frame: At the end 3-months after the end of the intervention
|
Participant's experiences of violence as well as the frequency and intensity of thse experiences will be assessed using established measures of intimate partner violence
|
At the end 3-months after the end of the intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mona Mittal, PhD, University of Rochester
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RSRB00040309
- 7K01MH080660 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Risk Reduction
-
Yale UniversityCompleted
-
University of Southern CaliforniaCenters for Disease Control and Prevention; Charles Drew University of Medicine...CompletedHIV | Risk Reduction BehaviorUnited States
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompletedRisk ReductionSouth Africa
-
University of California, San FranciscoUniversity of MiamiCompletedRisk ReductionUnited States
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompleted
-
Charite University, Berlin, GermanyRecruitingAnesthesiological Risk Reduction | Intensive Care Risk ReductionGermany
-
University of South FloridaNational Institute of Mental Health (NIMH)Unknown
-
University of ConnecticutNational Institute of Mental Health (NIMH)CompletedRisk Reduction | HIV-1 Infection
-
Colorado State UniversityUniversity of Colorado, Denver; United States Department of Agriculture (USDA) and other collaboratorsRecruitingMental Health Wellness | Lifestyle Risk Reduction | Family ResearchUnited States
-
Public Health Foundation Enterprises, Inc.San Francisco Department of Public Health; Alto PharmacyRecruitingHIV Prevention | Adherence, Medication | Risk Reduction | Pre-exposure Prophylaxis (PrEP)United States
Clinical Trials on community support group
-
University of Central FloridaAlzheimer's and Dementia Resource CenterCompletedDementia | Alzheimer's DiseaseUnited States
-
Elizabeth Glaser Pediatric AIDS FoundationMinistry of Health and Child Welfare, Zimbabwe; The Children's Investment Fund...CompletedHIV-infection/Aids
-
NMP Medical Research InstituteMacmillan Research Group UKCompleted
-
McMaster UniversitySt. Joseph's Healthcare HamiltonRecruitingPsychosis | Bipolar Disorder (BD)Canada
-
University of the PhilippinesPhilippine Dermatological SocietyCompleted
-
Foundation for Professional Development (Pty) LtdNational Institute of Mental Health (NIMH); National Institutes of Health (NIH) and other collaboratorsCompletedPrEP | HIV Prevention | Cost-effectiveness | AdolescenceSouth Africa
-
University of ArizonaNational Institute on Deafness and Other Communication Disorders (NIDCD)UnknownHearing LossUnited States
-
University of MinnesotaCompleted
-
Medstar Health Research InstituteGeorgetown University; George Washington University; Howard UniversityActive, not recruitingBreast Cancer | Prostate Cancer | Social Determinants of Health | Disparities | Health EquityUnited States
-
Stanford UniversityCalifornia Initiative to Advance Precision Medicine; Pacific Cancer Care; The... and other collaboratorsCompleted